Sept 15, 2026 Seoyoung Kang edition.cnn.com Moderna’s stock price recently rose after the company announced successful results from a Phase 3 clinical trial of a personalized mRNA cancer vaccine developed with Merck. This news has increased expectations that Moderna could enter the cancer treatment market. The outcome is especially important because it is the first positive Phase 3 result for a personalized mRNA-based cancer treatment. Moderna and Merck are now working toward